Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity
- PMID: 23643670
- PMCID: PMC3770844
- DOI: 10.1016/j.mrfmmm.2013.04.006
Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity
Abstract
Human DNA mismatch repair (MMR) recognizes and binds 5-fluorouracil (5FU) incorporated into DNA and triggers a MMR-dependent cell death. Absence of MMR in a patient's colorectal tumor abrogates 5FU's beneficial effects on survival. Changes in the tumor microenvironment like low extracellular pH (pHe) may diminish DNA repair, increasing genomic instability. Here, we explored if low pHe modifies MMR recognition of 5FU, as 5FU can exist in ionized and non-ionized forms depending on pH. We demonstrate that MMR-proficient cells at low pHe show downregulation of hMLH1, whereas expression of TDG and MBD4, known DNA glycosylases for base excision repair (BER) that can remove 5FU from DNA, were unchanged. We show in vitro that 5FU within DNA pairs with adenine (A) at high and low pH (in absence of MMR and BER). Surprisingly, 5FdU:G was repaired to C:G in hMLH1-deficient cells cultured at both low and normal pHe, similar to MMR-proficient cells. Moreover, both hMSH6 and hMSH3, components of hMutSα and hMutSβ, respectively, bound 5FU within DNA (hMSH6>hMSH3) but is influenced by hMLH1. We conclude that an acidic tumor microenvironment triggers downregulation of hMLH1, potentially removing the execution component of MMR for 5FU cytotoxicity, whereas other mechanisms remain stable to implement overall 5FU sensitivity.
Copyright © 2013 Elsevier B.V. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.Cancer Biol Ther. 2016 Jul 2;17(7):760-8. doi: 10.1080/15384047.2016.1178430. Epub 2016 Apr 26. Cancer Biol Ther. 2016. PMID: 27115207 Free PMC article.
-
DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.Cancer Biol Ther. 2011 Oct 15;12(8):756-64. doi: 10.4161/cbt.12.8.17169. Epub 2011 Oct 15. Cancer Biol Ther. 2011. PMID: 21814034 Free PMC article.
-
Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.Cancer Res. 2001 Jul 1;61(13):5193-201. Cancer Res. 2001. PMID: 11431359
-
Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis.Eur J Cancer Prev. 2014 Jul;23(4):246-57. doi: 10.1097/CEJ.0000000000000019. Eur J Cancer Prev. 2014. PMID: 24614649 Review.
-
Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities.Mutat Res. 2013 Mar-Apr;743-744:53-66. doi: 10.1016/j.mrfmmm.2012.12.008. Epub 2013 Feb 4. Mutat Res. 2013. PMID: 23391514 Free PMC article. Review.
Cited by
-
EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression.Genes (Basel). 2015 Mar 31;6(2):185-205. doi: 10.3390/genes6020185. Genes (Basel). 2015. PMID: 25836926 Free PMC article. Review.
-
Explosive mutation accumulation triggered by heterozygous human Pol ε proofreading-deficiency is driven by suppression of mismatch repair.Elife. 2018 Feb 28;7:e32692. doi: 10.7554/eLife.32692. Elife. 2018. PMID: 29488881 Free PMC article.
-
Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.World J Gastroenterol. 2015 Aug 21;21(31):9253-61. doi: 10.3748/wjg.v21.i31.9253. World J Gastroenterol. 2015. PMID: 26309352 Free PMC article. Review.
-
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy.Sci Adv. 2020 Jul 3;6(27):eaba8564. doi: 10.1126/sciadv.aba8564. eCollection 2020 Jul. Sci Adv. 2020. PMID: 32923587 Free PMC article.
-
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.Cancer Biol Ther. 2016 Jul 2;17(7):760-8. doi: 10.1080/15384047.2016.1178430. Epub 2016 Apr 26. Cancer Biol Ther. 2016. PMID: 27115207 Free PMC article.
References
-
- Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology. 2000;118:S115–S128. - PubMed
-
- Laurie LA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447–1456. - PubMed
-
- Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. - PubMed
-
- Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–326. - PubMed
-
- Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol. 1998;16:301–308. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
